InstilBio unTIL cancer is cured

# ABOUT

Instil Bio, Inc is a global, clinical-stage cell therapy company developing tumor infiltrating lymphocytes (TIL) therapies for the treatment of cancer. We are building on the decades-long foundation of TIL efficacy in treating solid tumors, applying our cell therapy experience and TIL manufacturing platform to bring the promise of TIL therapy to patients in need.

Instil Bio has research and cell therapy manufacturing facilities in Los Angeles, CA and Manchester, UK, with corporate offices in Dallas, TX.

# EVOLUTION OF TIL THERAPY MANUFACTURING

TIL manufacturing is a complex process that has historically relied on manual handling and highly skilled staff and, as such, has limited TIL cell therapy to a small number of specialized academic centers. Instil Bio has optimized and automated TIL manufacturing to improve the robustness, consistency, and scalability of the TIL manufacturing process to enable multicenter clinical trials with centralized manufacturing. A 95,000+ sq.ft. GMP and R&D facility is planned to open in 2023.



**INSTIL BIO MEDICAL INFORMATION** | EMAIL: *medical@instilbio.com*

# CELL JOURNEY

TILs are harvested from resected tumor tissue and grown ex vivo in a manufacturing process that generally consists of coculturing tumor and T cells followed by rapid T-cell expansion. In Instil Bio's process, the tumor is resected and immediately digested and cryopreserved, allowing dissociation of surgery and manufacturing process. This offers ultimate scheduling flexibility for patients and physicians for both tumor resection and TIL treatment. Instil Bio is committed to ongoing improvement in delivery of TIL therapy through in-house, end-to-end control of manufacturing.




**Surgical Resection**
Tumor is collected from the surgical site by a trained specialist

**Digestion To Single-Cell Suspension**
Automated tumor digestion results in a single-cell suspension of TILs and tumor cells

**Cryopreservation**
All cells are immediately cryopreserved and shipped to manufacturing site

**Outgrowth & Rapid Expansion**
Once thawed, all cells are cultured and expanded to achieve the final therapeutic dose of TILs

**Cryopreservation & Infusion**
Cryopreserved TIL product shipped back to clinical site for TIL infusion

# PIPELINE

ITIL-168 is a single infusion of unrestricted TIL cell therapy that unlocks the diversity of a patient's own immune cells to address the clonal heterogeneity of solid tumors and improve patient outcomes.




ITIL-306 is a TIL cell therapy engineered with a synthetic, FOLR1-directed CoStAR to enhance the activity of TILs within the tumor microenvironment.

CoStAR, CoStimulatory Antigen Receptor; CSCC, cutaneous squamous cell carcinoma; FOLR1, folate receptor alpha; GYN, gynecological malignancies; HNSCC, head and neck squamous cell carcinoma; IND, investigational new drug; NSCLC, non-small cell lung cancer; TIL, tumor-infiltrating lymphocyte.

# DELTA-1 STUDY

DELTA-1 is an ongoing global, multicenter, single-arm phase 2 study evaluating the efficacy and safety of ITIL-168, an unrestricted autologous TIL cell therapy in patients with advanced melanoma.




Made from each patient's digested and cryopreserved tumor, ITIL-168 is an TIL cell therapy manufactured to offer an unrestricted TCR repertoire.

## Adult Patients With Advanced Cutaneous Melanoma

**Cohort 1 (R/R; n=80):** R/R after ≥1 prior line of systemic therapy, including a PD-1 inhibitor[a]

**Cohort 2 (Intolerant to PD-1 inhibitor; n=25):** Intolerant to PD-1 inhibitor and have persistent disease after PD-1 inhibitor discontinuation[a]

**Cohort 3 (SD on PD-1 inhibitor; n=25):** Best response of SD after ≥4 doses of PD-1 inhibitor in previous line of therapy[a]

**Primary Endpoints:** ORR per central review[b]
**Key Secondary Endpoints:** DOR | TTR | PFS | OS | Safety | QOL | Biomarkers

[a]Patients with a BRAF mutation must have progressed after receiving a BRAF inhibitor ± a MEK inhibitor.
[b]Modified RECIST v1.1.
clinicaltrials.gov: TBD
DOR, duration of response; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; QOL, quality of life; R/R, relapsed/refractory; SD, stable disease; TIL, tumor-infiltrating lymphocyte; TTR, time to response.